The company’s lead product candidate, CNTX-4975, has been shown in clinical studies to provide significant and durable relief from localized moderate to severe knee OA pain by the second day.
The company’s lead product candidate, CNTX-4975, has been shown in clinical studies to provide significant and durable relief from localized moderate to severe knee OA pain by the second day.